Results 201 to 210 of about 114,856 (264)

14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

open access: yesAdvanced Science, EarlyView.
Integrative multi‐cohort analyses identify 14‐3‐3γ as a biomarker and regulator of cognitive vulnerability. Experimental studies show that 14‐3‐3γ loss is associated with Tau Thr205 phosphorylation, synaptic dysfunction, and cognitive impairment, while genetic overexpression or pharmacological stabilization of 14‐3‐3γ confers protective effects in ...
Shouqiang Zhu   +5 more
wiley   +1 more source

Polar lipids modify Alzheimer's Disease pathology by reducing astrocyte pro-inflammatory signaling through platelet-activating factor receptor (PTAFR) modulation. [PDF]

open access: yesLipids Health Dis
Hans S   +8 more
europepmc   +1 more source

Carrier‐Free Stimulus‐Responsive Theranostic Nanoprodrug Enabling GSH‐Consumption‐Promoted Chemo‐Photodynamic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Leveraging the critical role of glutathione (GSH) in mediating drug resistance and scavenging reactive oxygen species (ROS) in cancer cells, a carrier‐free GSH‐consuming theranostic nanoprodrug, consisting of a BODIPY photosensitizer and the chemotherapeutic drug paclitaxel linked through a GSH‐consuming drug linker, is developed to deeply explore the ...
Hansheng Huang, Binglin Sui
wiley   +1 more source

Platelet activating factor in allergies

open access: yesInternational Journal of Immunopathology and Pharmacology, 2015
The platelet-activating factor (PAF) produced and released by mast cells, basophils, neutrophils, eosinophils, fibroblasts, platelets, endothelial cells, and even cardiac muscle cells plays an important role in inflammatory and thrombotic diseases. PAF has been shown to be an important mediator in anaphylaxis.
Zbigniew Bartuzi
exaly   +3 more sources

Platelet-activating factor antagonists

Clinical Reviews in Allergy, 1995
The great number of PAF antagonists reviewed in this article clearly shows the tremendous effort made in the last 20 yr to explore the complex biological background of the mechanism of action of PAF and the potential clinical benefit of its antagonists. It is obvious that now highly potent, long-acting, and perorally applicable PAF-receptor antagonists
M, Koltai, P G, Braquet
openaire   +4 more sources

Radioimmunoassay for platelet‐activating factor

Lipids, 1991
AbstractA radioimmunoassay (RIA) for measurement of platelet‐activating factor (PAF) was developed. At a final antiserum dilution of 1∶640, the lowest detection limit of PAF was 0.1 pmol (50 pg). The standard curve obtained was suitable for measurement of PAF in amounts ranging from 0.1 pmol to 30 pmol. The antiserum showed high specificity.
K, Karasawa   +5 more
openaire   +2 more sources

Platelet-activating factor receptor

Prostaglandins & Other Lipid Mediators, 2002
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid mediator. Although PAF was named for its potential to induce platelet aggregation, intense investigations have elucidated potent biological actions of PAF in a broad range of cell types and tissues.
Zen-ichiro, Honda   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy